At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 191 enrolled
Drug / intervention
PF-04447943 +1 moredrug
Likely dose
PF-04447943 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2 MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE
In Brief
A Phase 2 clinical trial evaluating PF-04447943 and Placebo for Alzheimer's Disease. Completed, enrolled 191 participants across 44 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo; and determine the levels of PF-04447943 in the plasma over the course of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesCanada, Chile, Czechia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartSep 2009
Primary CompletionSep 2010
TodayJul 2026
First PostedJun 30, 2009
Enrollment StartSep 10, 2009
Primary CompletionSep 22, 2010
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 17.0 years ago
Interventions
PF-04447943drug
tablets, 25 mg every 12 hours for 12 wks
Placebodrug
matching placebo tablets, every 12 hours for 12 wks